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Women harboring mutations in the tumor suppressor 
gene  BRCA1 (breast cancer 1, early onset) have a 
profound predisposition to early-onset breast or ovarian 
cancer or both. BRCA1-associated breast tumors are 
characteristically ‘basal-like’, containing minimal estrogen 
receptor (ER), progesterone receptor (PR), and HER2 and 
expressing ‘basal’ cytokeratins and epidermal growth 
factor receptor. Basal-like tumors were originally deﬁ  ned 
on the basis of microarray studies, in which their 
molecular signature suggested similarities to basal cells 
resident in normal breast epithelium. Such observations 
led to the hypothesis that BRCA1-associated tumors 
arose from stem cells. Moreover, mammary stem cells 
exhibit a similar ‘triple-negative’ phenotype.
BRCA1 plays a crucial role in orchestrating the 
response to double-stranded DNA damage but is 
recog  nized to have multiple other functions. In vitro 
cellular assays have indicated roles in regulating 
mammary epithelial cell proliferation and diﬀ  erentiation 
and in promoting luminal-to-basal lineage transdiﬀ  er  en-
tiation [1-4]. Th   e ability to fractionate mammary 
epithelium into diﬀ  erent subtypes has enabled insights 
into target cells prone to tumorigenesis. Using human 
breast tissue, Liu et al. [5] observed that BRCA1 was 
required for ER-negative stem/progenitor cells to diﬀ  er-
entiate into mature ER-positive luminal cells. Lim et al.
[6] evaluated pathologically normal primary breast tissue 
samples from haploinsuﬃ   cient  BRCA1 patients and 
identiﬁ   ed an aberrant luminal progenitor population 
with factor-independent growth properties. A similar 
observation was made in Brca1-deﬁ   cient mice [6]. 
Consistent with a luminal progenitor cell defect, breast 
tissue from BRCA1 mutation carriers generally showed 
an increase in this subset relative to the total epithelial 
population. More  over, the molecular signature of luminal 
progenitor cells was found to be more similar to that of 
basal-like tumors than to that of any other tumor subtype 
[6]. Overall, these ﬁ  ndings indicated, but did not prove, 
that luminal progenitors are the ‘cells-of-origin’ for basal-
like tumors arising in BRCA1 carriers. An impor  tant 
study by Molyneux et al. [7] conditionally deleted Brca1
in diﬀ  erent epithelial populations (hetero  zygous for p53) 
and revealed that luminal rather than basal cells were 
predisposed to basal-like mammary tumors. Th  ese in 
vivo experiments provided direct evidence that BRCA1-
associated breast cancers can arise from luminal ER-
negative progenitors.
A recent study by Proia et al. [8] further highlighted the 
relevance of luminal cells in haplo  insuﬃ     cient  BRCA1
human breast tissue. With an elegant in vivo assay, fresh 
breast epithelial cells from wild-type or BRCA1+/mut
women were simultaneously transduced with potent 
lentiviruses encoding mutant p53, cyclin D1, activated 
phosphoinositide 3-kinase (PI3K), and oncogenic K-ras 
and implanted into human  ized mammary fat pads of 
nonobese diabetic/severe combined immunodeﬁ  ciency 
disease (NOD/SCID) mice. Whereas luminal and basal-
like tumors arose in mice implanted with wild-type cells, 
BRCA1+/mut cells largely yielded basal-like tumors, 
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dictates tumor phenotype. Proia et al. [8] also used 
epithelial subsets to demonstrate prefer  en  tial transfor-
mation of luminal compared to basal cells.
Gene proﬁ   ling of wild-type and BRCA1+/mut breast 
epithelia generated a molecular signa  ture enriched for 
Wnt, Notch, and melanogenesis signal  ing pathways in 
BRCA1+/mut tissue. Th  ose  ﬁ  ndings prompted an evaluation 
of the transcriptional repressor SLUG, which can be 
activated by these pathways. SLUG is a member of the 
SNAIL family and has been shown to have an important 
role in coordinating the epithelial-mesenchymal transi-
tion and pro  gram  ming cells toward a basal-like pheno-
type in breast cancer [9-11]. SLUG is normally expressed 
in the basal/stem cell-enriched population in both mice 
and humans [12]. Interestingly, although SLUG mRNA 
levels were unperturbed in BRCA1+/mut tissue, abundant 
levels of SLUG protein were observed. Moreover, knock-
down of BRCA1 by short interfering RNAs in breast cell 
lines resulted in a twofold increase in SLUG protein. 
Con  versely, knockdown of SLUG in breast epithelial cells 
biased them toward a more luminal cell fate [8]. Th  us, 
BRCA1 appears to regulate SLUG protein stability, and 
this may directly inﬂ  uence the cell fate speciﬁ  cation of 
luminal progenitor cells. Th   e precise mechanism through 
which BRCA1 contributes to SLUG protein stabilization 
remains to be elucidated. A direct interaction between 
SLUG with BRCA1 was not found, nor did knockdown of 
the BRCA1-associated RING domain-1 protein (BARD1) 
alter SLUG levels [8]. Th  e interesting link between 
BRCA1 and SLUG in perturbing cell fate decisions will 
undoubtedly form the basis of future studies.
Despite similarities in the epithelial subsets deﬁ  ned by 
EpCAM and CD49f by Proia et al.  [8], there are also 
some noteworthy diﬀ   erences. In contrast to previous 
authors [6,13,14], Proia et al.  [8] describe two potentially 
distinct basal subsets: an EpCAMlow popula  tion (‘basal/
myoepithelial’) and an EpCAM– population (‘mesen  chy-
mal’ or ‘basal progenitor’) [15], the latter of which appears 
to be novel. Th  is subset was found to be expanded in 
BRCA1+/mut breast tissue (with no change in the luminal 
progenitor subset) and was attributed to diversion of 
luminal cells toward a basal cell fate. On the other hand, 
we observed a signiﬁ  cant decrease in the basal subset [6] 
as well as reduced numbers of mammary stem cells in 
mice. In addition, the mature luminal sub  population 
contained a dramatically increased number of CK5/6-
expressing cells and fewer PR-positive cells, consistent 
with a perturbation in diﬀ   er en tiation  [6].  Th  ese  diﬀ  ering 
observations may, in part, reﬂ  ect  diﬀ  erent  methodo-
logical approaches (magnetic beads versus ﬂ  ow  cyto-
metry for lineage depletion) and gating strategies used 
for cell fractionation as well as possible variation between 
breast samples. Of the 12 BRCA1+/mut samples described 
by Proia et al. [8], at least a third of patients had prior 
breast cancer. Chemotherapy or endocrine therapy may 
modify epithelial cell composi  tion. Regardless of these 
diﬀ   erences, both studies identify BRCA1 as a key 
regulator of luminal cells.
In summary, one striking consequence of BRCA1 
deﬁ  ci  ency in mammary epithelium appears to be per-
turbed cell fate speciﬁ  cation, in which luminal cells are 
biased toward a more basal-like phenotype [8]. Luminal 
progenitor cells presumably depend, in part, on BRCA1 
for providing high-ﬁ  delity DNA repair, as they are highly 
proliferative. Altered proliferative and diﬀ  eren  tiative 
properties, compounded by a predisposition to genomic 
instability, are likely to set the stage for neoplastic trans-
formation. It seems likely that somatic gene silencing of 
BRCA1 through epigenetic mechanisms plays a similarly 
important role in sporadic basal-like breast cancer. 
Further elucidation of molecular pertur  bations resulting 
from BRCA1 deﬁ  ciency will hopefully provide important 
clues on therapeutic targets relevant to breast cancer 
treatment and chemoprevention for high-risk women.
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